PMC:7074432 / 4035-4632 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"169","span":{"begin":193,"end":198},"obj":"Gene"},{"id":"170","span":{"begin":317,"end":322},"obj":"Gene"},{"id":"171","span":{"begin":387,"end":392},"obj":"Gene"},{"id":"172","span":{"begin":505,"end":510},"obj":"Gene"},{"id":"173","span":{"begin":101,"end":109},"obj":"Species"},{"id":"174","span":{"begin":110,"end":118},"obj":"Species"},{"id":"175","span":{"begin":490,"end":499},"obj":"Species"},{"id":"176","span":{"begin":132,"end":141},"obj":"Chemical"},{"id":"177","span":{"begin":435,"end":441},"obj":"Chemical"},{"id":"178","span":{"begin":559,"end":580},"obj":"Chemical"},{"id":"179","span":{"begin":85,"end":96},"obj":"Disease"}],"attributes":[{"id":"A169","pred":"tao:has_database_id","subj":"169","obj":"Gene:3439"},{"id":"A170","pred":"tao:has_database_id","subj":"170","obj":"Gene:3439"},{"id":"A171","pred":"tao:has_database_id","subj":"171","obj":"Gene:3439"},{"id":"A172","pred":"tao:has_database_id","subj":"172","obj":"Gene:3439"},{"id":"A173","pred":"tao:has_database_id","subj":"173","obj":"Tax:694009"},{"id":"A174","pred":"tao:has_database_id","subj":"174","obj":"Tax:9606"},{"id":"A175","pred":"tao:has_database_id","subj":"175","obj":"Tax:2697049"},{"id":"A176","pred":"tao:has_database_id","subj":"176","obj":"MESH:D012254"},{"id":"A177","pred":"tao:has_database_id","subj":"177","obj":"MESH:D010100"},{"id":"A178","pred":"tao:has_database_id","subj":"178","obj":"MESH:C558899"},{"id":"A179","pred":"tao:has_database_id","subj":"179","obj":"MESH:D006509"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Interferons (IFNs) are broad-spectrum antivirals, primarily used in the treatment of hepatitis B. In SARS-CoV patients, compared to ribavirin or interferon (IFN) alone, the benefit was seen on IFN-α + high-dose corticosteroid group.[20] Other observational studies also support these findings and the combined use of IFN-α and corticosteroid (corticosteroid arm n = 13; corticosteroid + IFN-α arm n = 9) showed less disease-associated oxygen saturation impairment.[21] For the treatment of 2019-nCoV (7), IFN-α (5 million U bid inh) is recommended along with lopinavir + ritonavir combination.[17]"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T180","span":{"begin":101,"end":109},"obj":"SP_10"},{"id":"T179","span":{"begin":132,"end":141},"obj":"DG_29"},{"id":"T178","span":{"begin":211,"end":225},"obj":"CHEBI:50858;CHEBI:50858"},{"id":"T177","span":{"begin":327,"end":341},"obj":"CHEBI:50858;CHEBI:50858"},{"id":"T176","span":{"begin":343,"end":357},"obj":"CHEBI:50858;CHEBI:50858"},{"id":"T175","span":{"begin":370,"end":384},"obj":"CHEBI:50858;CHEBI:50858"},{"id":"T174","span":{"begin":490,"end":499},"obj":"SP_7"},{"id":"T173","span":{"begin":559,"end":568},"obj":"CHEBI:6426;DG_23;CHEBI:6426"},{"id":"T172","span":{"begin":571,"end":580},"obj":"CHEBI:85129;DG_30;CHEBI:85129"}],"text":"Interferons (IFNs) are broad-spectrum antivirals, primarily used in the treatment of hepatitis B. In SARS-CoV patients, compared to ribavirin or interferon (IFN) alone, the benefit was seen on IFN-α + high-dose corticosteroid group.[20] Other observational studies also support these findings and the combined use of IFN-α and corticosteroid (corticosteroid arm n = 13; corticosteroid + IFN-α arm n = 9) showed less disease-associated oxygen saturation impairment.[21] For the treatment of 2019-nCoV (7), IFN-α (5 million U bid inh) is recommended along with lopinavir + ritonavir combination.[17]"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T4","span":{"begin":358,"end":361},"obj":"Body_part"},{"id":"T5","span":{"begin":393,"end":396},"obj":"Body_part"}],"attributes":[{"id":"A4","pred":"fma_id","subj":"T4","obj":"http://purl.org/sig/ont/fma/fma24890"},{"id":"A5","pred":"fma_id","subj":"T5","obj":"http://purl.org/sig/ont/fma/fma24890"}],"text":"Interferons (IFNs) are broad-spectrum antivirals, primarily used in the treatment of hepatitis B. In SARS-CoV patients, compared to ribavirin or interferon (IFN) alone, the benefit was seen on IFN-α + high-dose corticosteroid group.[20] Other observational studies also support these findings and the combined use of IFN-α and corticosteroid (corticosteroid arm n = 13; corticosteroid + IFN-α arm n = 9) showed less disease-associated oxygen saturation impairment.[21] For the treatment of 2019-nCoV (7), IFN-α (5 million U bid inh) is recommended along with lopinavir + ritonavir combination.[17]"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T1","span":{"begin":358,"end":361},"obj":"Body_part"},{"id":"T2","span":{"begin":393,"end":396},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0001460"},{"id":"A2","pred":"uberon_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/UBERON_0001460"}],"text":"Interferons (IFNs) are broad-spectrum antivirals, primarily used in the treatment of hepatitis B. In SARS-CoV patients, compared to ribavirin or interferon (IFN) alone, the benefit was seen on IFN-α + high-dose corticosteroid group.[20] Other observational studies also support these findings and the combined use of IFN-α and corticosteroid (corticosteroid arm n = 13; corticosteroid + IFN-α arm n = 9) showed less disease-associated oxygen saturation impairment.[21] For the treatment of 2019-nCoV (7), IFN-α (5 million U bid inh) is recommended along with lopinavir + ritonavir combination.[17]"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T19","span":{"begin":85,"end":96},"obj":"Disease"},{"id":"T20","span":{"begin":85,"end":94},"obj":"Disease"},{"id":"T21","span":{"begin":101,"end":109},"obj":"Disease"}],"attributes":[{"id":"A19","pred":"mondo_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/MONDO_0005344"},{"id":"A20","pred":"mondo_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/MONDO_0002251"},{"id":"A21","pred":"mondo_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"Interferons (IFNs) are broad-spectrum antivirals, primarily used in the treatment of hepatitis B. In SARS-CoV patients, compared to ribavirin or interferon (IFN) alone, the benefit was seen on IFN-α + high-dose corticosteroid group.[20] Other observational studies also support these findings and the combined use of IFN-α and corticosteroid (corticosteroid arm n = 13; corticosteroid + IFN-α arm n = 9) showed less disease-associated oxygen saturation impairment.[21] For the treatment of 2019-nCoV (7), IFN-α (5 million U bid inh) is recommended along with lopinavir + ritonavir combination.[17]"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T18","span":{"begin":95,"end":96},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"},{"id":"T19","span":{"begin":358,"end":361},"obj":"http://www.ebi.ac.uk/efo/EFO_0001410"},{"id":"T20","span":{"begin":393,"end":396},"obj":"http://www.ebi.ac.uk/efo/EFO_0001410"}],"text":"Interferons (IFNs) are broad-spectrum antivirals, primarily used in the treatment of hepatitis B. In SARS-CoV patients, compared to ribavirin or interferon (IFN) alone, the benefit was seen on IFN-α + high-dose corticosteroid group.[20] Other observational studies also support these findings and the combined use of IFN-α and corticosteroid (corticosteroid arm n = 13; corticosteroid + IFN-α arm n = 9) showed less disease-associated oxygen saturation impairment.[21] For the treatment of 2019-nCoV (7), IFN-α (5 million U bid inh) is recommended along with lopinavir + ritonavir combination.[17]"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T47","span":{"begin":38,"end":48},"obj":"Chemical"},{"id":"T48","span":{"begin":132,"end":141},"obj":"Chemical"},{"id":"T49","span":{"begin":145,"end":155},"obj":"Chemical"},{"id":"T50","span":{"begin":157,"end":160},"obj":"Chemical"},{"id":"T51","span":{"begin":193,"end":196},"obj":"Chemical"},{"id":"T52","span":{"begin":211,"end":225},"obj":"Chemical"},{"id":"T53","span":{"begin":226,"end":231},"obj":"Chemical"},{"id":"T54","span":{"begin":317,"end":320},"obj":"Chemical"},{"id":"T55","span":{"begin":327,"end":341},"obj":"Chemical"},{"id":"T56","span":{"begin":343,"end":357},"obj":"Chemical"},{"id":"T57","span":{"begin":370,"end":384},"obj":"Chemical"},{"id":"T58","span":{"begin":387,"end":390},"obj":"Chemical"},{"id":"T59","span":{"begin":435,"end":441},"obj":"Chemical"},{"id":"T60","span":{"begin":505,"end":508},"obj":"Chemical"},{"id":"T61","span":{"begin":559,"end":568},"obj":"Chemical"},{"id":"T62","span":{"begin":571,"end":580},"obj":"Chemical"}],"attributes":[{"id":"A47","pred":"chebi_id","subj":"T47","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A48","pred":"chebi_id","subj":"T48","obj":"http://purl.obolibrary.org/obo/CHEBI_63580"},{"id":"A49","pred":"chebi_id","subj":"T49","obj":"http://purl.obolibrary.org/obo/CHEBI_52999"},{"id":"A50","pred":"chebi_id","subj":"T50","obj":"http://purl.obolibrary.org/obo/CHEBI_52999"},{"id":"A51","pred":"chebi_id","subj":"T51","obj":"http://purl.obolibrary.org/obo/CHEBI_52999"},{"id":"A52","pred":"chebi_id","subj":"T52","obj":"http://purl.obolibrary.org/obo/CHEBI_50858"},{"id":"A53","pred":"chebi_id","subj":"T53","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A54","pred":"chebi_id","subj":"T54","obj":"http://purl.obolibrary.org/obo/CHEBI_52999"},{"id":"A55","pred":"chebi_id","subj":"T55","obj":"http://purl.obolibrary.org/obo/CHEBI_50858"},{"id":"A56","pred":"chebi_id","subj":"T56","obj":"http://purl.obolibrary.org/obo/CHEBI_50858"},{"id":"A57","pred":"chebi_id","subj":"T57","obj":"http://purl.obolibrary.org/obo/CHEBI_50858"},{"id":"A58","pred":"chebi_id","subj":"T58","obj":"http://purl.obolibrary.org/obo/CHEBI_52999"},{"id":"A59","pred":"chebi_id","subj":"T59","obj":"http://purl.obolibrary.org/obo/CHEBI_25805"},{"id":"A60","pred":"chebi_id","subj":"T60","obj":"http://purl.obolibrary.org/obo/CHEBI_52999"},{"id":"A61","pred":"chebi_id","subj":"T61","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A62","pred":"chebi_id","subj":"T62","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"}],"text":"Interferons (IFNs) are broad-spectrum antivirals, primarily used in the treatment of hepatitis B. In SARS-CoV patients, compared to ribavirin or interferon (IFN) alone, the benefit was seen on IFN-α + high-dose corticosteroid group.[20] Other observational studies also support these findings and the combined use of IFN-α and corticosteroid (corticosteroid arm n = 13; corticosteroid + IFN-α arm n = 9) showed less disease-associated oxygen saturation impairment.[21] For the treatment of 2019-nCoV (7), IFN-α (5 million U bid inh) is recommended along with lopinavir + ritonavir combination.[17]"}

{"project":"LitCovid-sentences","denotations":[{"id":"T25","span":{"begin":0,"end":97},"obj":"Sentence"},{"id":"T26","span":{"begin":98,"end":597},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Interferons (IFNs) are broad-spectrum antivirals, primarily used in the treatment of hepatitis B. In SARS-CoV patients, compared to ribavirin or interferon (IFN) alone, the benefit was seen on IFN-α + high-dose corticosteroid group.[20] Other observational studies also support these findings and the combined use of IFN-α and corticosteroid (corticosteroid arm n = 13; corticosteroid + IFN-α arm n = 9) showed less disease-associated oxygen saturation impairment.[21] For the treatment of 2019-nCoV (7), IFN-α (5 million U bid inh) is recommended along with lopinavir + ritonavir combination.[17]"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T6","span":{"begin":85,"end":94},"obj":"Phenotype"}],"attributes":[{"id":"A6","pred":"hp_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/HP_0012115"}],"text":"Interferons (IFNs) are broad-spectrum antivirals, primarily used in the treatment of hepatitis B. In SARS-CoV patients, compared to ribavirin or interferon (IFN) alone, the benefit was seen on IFN-α + high-dose corticosteroid group.[20] Other observational studies also support these findings and the combined use of IFN-α and corticosteroid (corticosteroid arm n = 13; corticosteroid + IFN-α arm n = 9) showed less disease-associated oxygen saturation impairment.[21] For the treatment of 2019-nCoV (7), IFN-α (5 million U bid inh) is recommended along with lopinavir + ritonavir combination.[17]"}

{"project":"2_test","denotations":[{"id":"32201439-12867568-47219416","span":{"begin":233,"end":235},"obj":"12867568"},{"id":"32201439-14693875-47219417","span":{"begin":465,"end":467},"obj":"14693875"},{"id":"32201439-32029004-47219418","span":{"begin":594,"end":596},"obj":"32029004"},{"id":"T43328","span":{"begin":233,"end":235},"obj":"12867568"},{"id":"T72085","span":{"begin":465,"end":467},"obj":"14693875"},{"id":"T4398","span":{"begin":594,"end":596},"obj":"32029004"}],"text":"Interferons (IFNs) are broad-spectrum antivirals, primarily used in the treatment of hepatitis B. In SARS-CoV patients, compared to ribavirin or interferon (IFN) alone, the benefit was seen on IFN-α + high-dose corticosteroid group.[20] Other observational studies also support these findings and the combined use of IFN-α and corticosteroid (corticosteroid arm n = 13; corticosteroid + IFN-α arm n = 9) showed less disease-associated oxygen saturation impairment.[21] For the treatment of 2019-nCoV (7), IFN-α (5 million U bid inh) is recommended along with lopinavir + ritonavir combination.[17]"}